Drug Profile
Research programme: ALK expression companion diagnostic - Insight Genetics/QIAGEN
Alternative Names: Anaplastic lymphoma kinase expression companion diagnostic - Insight Genetics/QIAGEN; Insight ALK ScreenLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Insight Genetics
- Developer Insight Genetics; QIAGEN
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Lung-cancer(Diagnosis) in Unknown
- 12 Nov 2012 Insight Genetics receives SBIR grant from National Cancer Institute for ALK expression companion diagnostic development in Lung cancer
- 31 Jan 2012 Insight Genetics' genetic test for the biomarker anaplastic lymphoma kinase licensed to QIAGEN